Kristine M. Wadosky, PhD – Women in Pathology

Kristine M Wadosky, PhD
Research Affiliate, Postdoctoral
Roswell Park Comprehensive Cancer Center
Department of Pharmacology and Therapeutics
Buffalo, NY

Dr. Wadosky completed both a B.S. in Molecular Genetics and a B.A. in English/Theater at the University of Rochester in 2009, graduating Magna Cum Laude and Phi Beta Kappa. She then began her Ph.D. training in Pathology at the University of North Carolina at Chapel Hill and defended her dissertation in 2014. Dr. Wadosky published 7 manuscripts based on her dissertation work, 4 of which are first-author, on the ubiquitin proteasome system in cardiac and skeletal muscle diseases. One of her dissertation projects was funded by a predoctoral grant awarded by the American Heart Association. During her graduate training, Dr. Wadosky also gave several oral presentations at national meetings on her dissertation work, for which she received trainee travel grants from both the American Society for Investigative Pathology (ASIP) and American Physiological Society (APS).

Dr. Wadosky came to Roswell Park Comprehensive Cancer Center in January 2015 for postdoctoral training, first joining the laboratory of Dr. Shahriar Koochekpour to study the mechanisms governing castration-resistant prostate cancer. In September 2016, Dr. Wadosky then joined the laboratory of Dr. David W. Goodrich. She has published three comprehensive review articles on treatment of advanced prostate cancer and therapy resistance, a research article on how FDA-approved drug riluzole has anti-tumor effects in prostate cancer by promoting androgen receptor protein degradation, and a methods video article on how to generate tumor organoids from genetically engineered mouse models of prostate cancer.

Dr. Wadosky’s main work focuses on how RB1 deficiency in advanced prostate cancer drives changes in cell lineage of prostate tumor cells. She is currently taking several approaches in her projects, including 3D organoid culturing, single cell RNA sequencing, and generating novel genetically engineered mouse models. Dr. Wadosky presented her work focusing on Ezh2’s role in cell lineage changes in RB1-deficient prostate cancer as an oral presentation at the 2018 Annual Meeting of the American Association for Cancer Research (see press release) and an update on this research was accepted as an oral presentation at the Annual Meeting of ASIP at Experimental Biology 2020. Dr. Wadosky also received the ASIP 2020 Monga-Hans Trainee Travel Award for Excellence in Neoplasia Research for this abstract.

In this video, Dr. Wadosky briefly discusses the background and rationale for her projects and then discusses how she developed a novel “neural” media for 3D organoid cell culture and shows RB1-deficient prostate tumor cells are uniquely capable of maintaining organoids of multiple lineages.

Too Much of a Good Thing: Effect of Prostate Cancer Gene Can Go Either Way, Roswell Park Researchers Find

Roswell Park researchers have found that the effect of a key gene driving an aggressive, recurrent and often incurable form of prostate cancer is dose-dependent, opening new avenues for therapies that overcome resistance to treatment of advanced disease.


kristinemwadosky@gmail.com
kristine.wadosky@roswellpark.org